TY - JOUR
T1 - A 3D deep learning model to predict the diagnosis of dementia with Lewy bodies, Alzheimer’s disease, and mild cognitive impairment using brain 18F-FDG PET
AU - Etminani, Kobra
AU - Soliman, Amira
AU - Davidsson, Anette
AU - Chang, Jose R.
AU - Martínez-Sanchis, Begoña
AU - Byttner, Stefan
AU - Camacho, Valle
AU - Bauckneht, Matteo
AU - Stegeran, Roxana
AU - Ressner, Marcus
AU - Agudelo-Cifuentes, Marc
AU - Chincarini, Andrea
AU - Brendel, Matthias
AU - Rominger, Axel
AU - Bruffaerts, Rose
AU - Vandenberghe, Rik
AU - Kramberger, Milica G.
AU - Trost, Maja
AU - Nicastro, Nicolas
AU - Frisoni, Giovanni B.
AU - Lemstra, Afina W.
AU - van Berckel, Bart N.M.
AU - Pilotto, Andrea
AU - Padovani, Alessandro
AU - Morbelli, Silvia
AU - Aarsland, Dag
AU - Nobili, Flavio
AU - Garibotto, Valentina
AU - Ochoa-Figueroa, Miguel
N1 - Funding Information:
Part of data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12–2-0012).
Funding Information:
Open access funding provided by Halmstad University. This study was part of a collaborative project between Center for Applied Intelligent System Research (CAISR) at Halmstad University, Sweden, and Department of Clinical Physiology, Department of Radiology and the Center for Medical Imaging Visualization (CMIV) at Linköping University Hospital, Sweden, and the European DLB consortium, which was funded by Analytic Imaging Diagnostics Arena (AIDA) initiative, jointly supported by VINNOVA (Grant 2017–02447), Formas and the Swedish Energy Agency. VG was supported by the Swiss National Science Foundation (projects 320030_169876, 320030_185028) and the Velux Foundation (project 1123). RB is a senior postdoctoral fellow of the Flanders Research Foundation (FWO 12I2121N).
Publisher Copyright:
© 2021, The Author(s).
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2021
Y1 - 2021
N2 - Purpose: The purpose of this study is to develop and validate a 3D deep learning model that predicts the final clinical diagnosis of Alzheimer’s disease (AD), dementia with Lewy bodies (DLB), mild cognitive impairment due to Alzheimer’s disease (MCI-AD), and cognitively normal (CN) using fluorine 18 fluorodeoxyglucose PET (18F-FDG PET) and compare model’s performance to that of multiple expert nuclear medicine physicians’ readers. Materials and methods: Retrospective 18F-FDG PET scans for AD, MCI-AD, and CN were collected from Alzheimer’s disease neuroimaging initiative (556 patients from 2005 to 2020), and CN and DLB cases were from European DLB Consortium (201 patients from 2005 to 2018). The introduced 3D convolutional neural network was trained using 90% of the data and externally tested using 10% as well as comparison to human readers on the same independent test set. The model’s performance was analyzed with sensitivity, specificity, precision, F1 score, receiver operating characteristic (ROC). The regional metabolic changes driving classification were visualized using uniform manifold approximation and projection (UMAP) and network attention. Results: The proposed model achieved area under the ROC curve of 96.2% (95% confidence interval: 90.6–100) on predicting the final diagnosis of DLB in the independent test set, 96.4% (92.7–100) in AD, 71.4% (51.6–91.2) in MCI-AD, and 94.7% (90–99.5) in CN, which in ROC space outperformed human readers performance. The network attention depicted the posterior cingulate cortex is important for each neurodegenerative disease, and the UMAP visualization of the extracted features by the proposed model demonstrates the reality of development of the given disorders. Conclusion: Using only 18F-FDG PET of the brain, a 3D deep learning model could predict the final diagnosis of the most common neurodegenerative disorders which achieved a competitive performance compared to the human readers as well as their consensus.
AB - Purpose: The purpose of this study is to develop and validate a 3D deep learning model that predicts the final clinical diagnosis of Alzheimer’s disease (AD), dementia with Lewy bodies (DLB), mild cognitive impairment due to Alzheimer’s disease (MCI-AD), and cognitively normal (CN) using fluorine 18 fluorodeoxyglucose PET (18F-FDG PET) and compare model’s performance to that of multiple expert nuclear medicine physicians’ readers. Materials and methods: Retrospective 18F-FDG PET scans for AD, MCI-AD, and CN were collected from Alzheimer’s disease neuroimaging initiative (556 patients from 2005 to 2020), and CN and DLB cases were from European DLB Consortium (201 patients from 2005 to 2018). The introduced 3D convolutional neural network was trained using 90% of the data and externally tested using 10% as well as comparison to human readers on the same independent test set. The model’s performance was analyzed with sensitivity, specificity, precision, F1 score, receiver operating characteristic (ROC). The regional metabolic changes driving classification were visualized using uniform manifold approximation and projection (UMAP) and network attention. Results: The proposed model achieved area under the ROC curve of 96.2% (95% confidence interval: 90.6–100) on predicting the final diagnosis of DLB in the independent test set, 96.4% (92.7–100) in AD, 71.4% (51.6–91.2) in MCI-AD, and 94.7% (90–99.5) in CN, which in ROC space outperformed human readers performance. The network attention depicted the posterior cingulate cortex is important for each neurodegenerative disease, and the UMAP visualization of the extracted features by the proposed model demonstrates the reality of development of the given disorders. Conclusion: Using only 18F-FDG PET of the brain, a 3D deep learning model could predict the final diagnosis of the most common neurodegenerative disorders which achieved a competitive performance compared to the human readers as well as their consensus.
KW - Alzheimer’s disease
KW - Artificial intelligence
KW - Deep learning
KW - Dementia with Lewy bodies
KW - FDG PET
KW - Mild cognitive impairment
UR - http://www.scopus.com/inward/record.url?scp=85111504097&partnerID=8YFLogxK
U2 - 10.1007/s00259-021-05483-0
DO - 10.1007/s00259-021-05483-0
M3 - Article
AN - SCOPUS:85111504097
SN - 1619-7070
JO - European Journal of Nuclear Medicine and Molecular Imaging
JF - European Journal of Nuclear Medicine and Molecular Imaging
ER -